SUMMARY Serum levels of the complement proteins C3, C4, Cl inhibitor (Cl INH), factor I (C3b inactivator) and factor H (BIH) and plasma levels of cleavage products of C3 (C3c) 
In acute pancreatitis activated proteases are released into the local glandular structure. Their role in the pathogenesis of the disease, however, is controversial. Normally, the presence of circulating protease inhibitors ensures that released proteolytic enzymes are quickly complexed but, in dogs with acute pancreatitis induced by a closed duodenal loop, when the inhibitors become saturated active trypsin becomes detectable in the ascitic fluid. This may then activate other proteases1 2 such as plasmin, Hagemann factor, and complement, which mediate an inflammatory reaction.
Interest has centred on the complement system as the mediator in acute pancreatitis. Not only are its components, in particular C3 and C5, susceptible to attack by trypsin36 but in human and experimental pancreatitis plasma C3 levels have been found to be depressed, sometimes associated with the presence of circulating C3 breakdown products.7-11 It has also been suggested that the magnitude and duration of such depression in patients gives an indication of the prognosis. 8 We have observed, however, that serum levels of ' C3c . We think that it is C3c because it has the same electrophoretic mobility as the C3c generated in aged serum and by trypsinisation. We have also identified C3d in pancreatitic serum in concentrations that parallel the breakdown fragment detected by immunofixation. This technique has a sensitivity of 002 g/l for C3c and 0O05 g/l for factor B breakdown products.
Standardisation of assays for C3, C4, and C1INH was performed against Atlantic Antibodies Calibrator. In the absence of available standards, values for factor I and factor H were expressed as a percentage of a normal serum pool derived from 20 adults. Normal ranges for these assays are: C3, 0.55-1.20 g/l; C4, 0.20-0.50 g/l; C1INH, 0.15-0-33 g/l; factor I, 66-146%, and factor H, 56-164%.
Results
Sequential measurements of complement components are presented in Figs. 1-6 both as concentrations and as the percentage change over the measurement on the day of admission, day 0. The Table shows the significance of the differences between the levels on days 1 to 4 and day 0 tested by a paired Student's t test.
COMPLEMENT BREAKDOWN PRODUCTS C3 breakdown was considered to be significant if C3c levels were greater than 10% of the total C3; levels below this may sometimes occur because of faulty blood sampling or prolonged storage of blood before separation. C3 breakdown was seen in 19 of the 26 patients. Breakdown was maximal on day 1 and showed a slight tendency to decrease over the four days (Fig. 1 ). Factor B breakdown was not encountered in any sample. COMPLEMENT COMPONENT LEVELS Total C3 concentration fell during the first day in those patients with C3 breakdown products. In the remaining seven, C3 increased on day 3 (Fig. 2 , Table) . C4 showed a slight tendency to increase over the four days but these changes were not statistically significant (Fig. 3 , Table) .
COMPLEMENT INHIBITOR LEVELS
C1INH and factor H both increased over the four days of the study. Factor I showed a slight fall followed by an increase (Figs. 4, 5, 6 , Table) .
RELATIONSHIP OF COMPLEMENT CHANGES TO CLINICAL COURSE
We were unable to show any relationship between C3 breakdown or changes in other complement components and the clinical severity of the pancreatitis. Profound C3 breakdown occurred in some patients with mild symptoms, while at least one severely shocked patient showed insignificant levels of the breakdown product C3c.
Discussion
The results confirm the findings of Goldstein et a17 that C3 levels fall and C3 breakdown products are present in some patients with acute pancreatitis. In contrast we have shown no decrease in C4 levels and also an absence of factor B breakdown products.
There is good evidence that proteolytic enzymesin particular, trypsin -cleave both Cl and C3.-6
The absence of a decrease in C4 levels in our patients suggests that cleavage of C3 is not mediated via activation of Cl but that it may be a direct effect of trypsin. The initial fall and subsequent rise in C3 concentration probably represents complement consumption as a result of breakdown followed by the effects of an acute phase response in which complement levels are known to increase.12 This interpretation is supported by the absence of an initial fall in C3 concentration in those patients who did not have C3 breakdown products in their plasma. The higher overall C3 levels in those patients with C3 breakdown suggests a more marked acute phase response in this group particularly on day 0. There was a tendency for those patients with higher initial C3 levels on day 0 also to have high factor I and factor H levels. It may thus be that the inflammatory reaction was more severe in these patients, although this was not apparent clinically. The levels on day 0 are therefore in no way baseline values and reflect the effects of a disease process which has been proceeding for a variable period of time before admission to hospital. The changes in concentrations of complement inhibitors support the suggestion that trypsin may be responsible for complement breakdown in pancreatitis. C1INH shows a significant increase in the acute phase in all patients regardless of the amount of C3 breakdown. There is thus no evidence of C1INH consumption as might be suspected if Cl activation were occurring. Both factor H and factor I showed a significant acute phase increase over the four days of the study. Factor I, however, showed a significant fall on day 1 suggesting the possibility of consumption by binding to C3b and subsequent rapid metabolism. This may occur because of the clearance of complexes from the circulation despite the fact that factor I is not consumed as a result of complement activation in vitro. The lack of a fall of factor H is interesting in view of the finding of Whaley et a115 who saw a fall in the levels of both factor I and factor H in Gram negative endotoxic shock with C3 activation. Factor I enzymatically inactivates C3b to form C3bi. Factor H binds to C3b and potentiates the activity of factor I, but it also dissociates the alternative pathway convertases C3bBb and C3bBbP by displacing Bb from the complexes, thus allowing the conversion of the C3b. Significant alternative pathway activation with factor B breakdown occurs in Gram negative endotoxic shock possibly consuming factor H as a result of binding to factor B-containing complexes. The lack of fall in factor H in pancreatitis may thus be related to the absence of factor B activation.
It has been suggested that complement effector molecules may be responsible for some of the systemic pathological changes occurring in pancreatitis. 8 
